Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Trastuzumab Plus Neratinib vs Trastuzumab Plus Pertuzumab in HR+/HER2+ Breast Cancer
NCT05760612Phase 3Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Mar 2023
- Primary completion
- Feb 2028
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of neratinib in breast cancer (2 arms), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Invasive Disease Free Survival at 3 years. Started Mar 2023; status: recruiting.
02
Drugs
neratinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05760612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05760612.